Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
Hagop M KantarjianKebede H BegnaJessica K AltmanStuart L GoldbergMikkael A SekeresStephen A StricklandMartha L ArellanoDavid F ClaxtonMaria R BaerMarc GautierEllin BermanKaren SeiterScott R SolomonGary J SchillerSelina M LugerAleksandra ButrymGianluca GaidanoXavier G ThomasPau MontesinosDavid A RizzieriDonald P QuickParameswaran VenugopalRakesh GaurLori J ManessTapan Mahendra KadiaFarhad RavandiMarc E BuyseJudy H ChiaoPublished in: Cancer (2021)
The regimen of decitabine administered in alternating cycles with sapacitabine was active but did not significantly improve OS compared with decitabine monotherapy. Subgroup analyses suggest that patients with baseline white blood cell counts <10 × 109 /L might benefit from decitabine alternating with sapacitabine, with an improved CR rate and the convenience of an oral drug. These findings should be prospectively confirmed.